Hypericin-PDT has reduced efficacy in colorectal cancer spheroids as compared to 2D cultures, which may be attributable through upregulation in ABCG2. The clinical efficacy of Hypericin-PDT may be enhanced by ABCG2 inhibition. This evidence concerns the gene ABCG2 and colorectal cancer.